Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leukocyte interferon-alpha plus ribavirin versus reduced-dose peginterferon plus ribavirin in chronic hepatitis C patients requiring peginterferon dose reduction
2005-005161-11Phase 3Terminated
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Mar 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa, ribavirin, peginterferon alfa-2a and peginterferon alfa-2b in hepatitis C virus infection (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Adverse events and End of treatment response. Started Mar 2006; status: terminated.
02
Drugs
interferon alfaribavirinpeginterferon alfa-2apeginterferon alfa-2b
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2005-005161-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005161-11.